LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling

  • Matsuda R
  • Enokida H
  • Chiyomaru T
 et al. 
  • 18


    Mendeley users who have this article in their library.
  • 24


    Citations of this article.


BACKGROUND: The aim of this study is to find a novel molecular target based on chromosomal alteration and array-based gene expression analyses in bladder cancer (BC). We investigated a cancer testis antigen, LY6K, which is located on chromosome 8q24.3.

METHODS: Five BC cell lines were subjected to high-resolution array-comparative genomic hybridisation with 244 000 probes. The expression levels of LY6K mRNA were evaluated in BC cell lines and clinical BC specimens by real-time reverse transcription-PCR. The cell lines were subjected to fluorescence in situ hybridisation of LY6K. Cell viability was evaluated by cell growth, wound healing, and matrigel invasion assays.

RESULTS: Typical gained loci (P
CONCLUSION: Upregulation of the oncogenic LY6K gene located on the gained locus at 8q24.3 may contribute BC development.

Author-supplied keywords

  • 8q24.3
  • LY6K
  • array-CGH
  • bladder cancer

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • R. Matsuda

  • H. Enokida

  • T. Chiyomaru

  • N. Kikkawa

  • T. Sugimoto

  • K. Kawakami

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free